BGI Genomics Co. Ltd. Class A

BGI Genomics Co. Ltd. Class A

SSZSE:300676
35.37
CNY
-0.46
(-1.28%)
-1.35EPS
19.18BMarket Cap
Apr 26Next Earn
BGI Genomics Co. Ltd. Class A
SZSE:300676
(Shenzhen Stock Exchange)

Recent

price

35.37

P/E

ratio

- -

div

yld

0.10%

ROIC.AI

2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
12.84
12.8
4.43
3.87
4.73
5.53
6.34
7
21.1
16.5
17.19
10.61
9.38
8.9
8.94
Revenue per Share
1.32
1.66
0.11
0.77
0.92
1.05
0.97
0.69
5.25
3.56
1.96
0.23
-2.19
-1.48
-1.31
Basic EPS, GAAP
0.17
-3.03
-2.21
0.44
-0.03
-0.13
-1.66
-1.01
8.3
5.1
-2.77
-2.02
-1.05
-1.37
- -
Free Cash Flow per Basic Share
0.01
- -
- -
- -
0.23
0.29
0.5
0.1
0.16
0.43
0.41
1.02
0.12
0.04
0.04
Dividend per Share
0.31
1.11
3.29
8.6
9.33
10.37
10.13
10.91
14.77
22.51
24.34
23.82
21.97
20.31
19.7
Book Value per Share
0.31
0.52
2.73
8.07
8.86
9.97
9.61
10.35
14.21
21.62
22.95
22.3
20.66
19.1
18.58
Tangible Book Value per Share
62
82
256
340
362
379
400
400
398
410
410
410
412
416
417
Basic Weighted Avg Shares
795
1,047
1,132
1,319
1,711
2,096
2,536
2,800
8,397
6,766
7,053
4,350
3,867
3,705
3,725
Sales/Revenue/Turnover
15.8
20.88
5.51
20.12
19.12
23.17
19.43
14.42
33.5
27.31
17.75
5.32
-10.58
-4.59
-2.29
Operating Margin (%)
20
41
91
89
95
113
169
241
302
371
453
437
484
518
- -
Depreciation Expense
82
136
28
262
333
398
387
276
2,090
1,462
803
93
-903
-617
-545
Net Income, GAAP
19.65
15.63
21.87
16.08
14.56
14.6
14.12
15.13
13.93
15.36
19.62
18.92
- -
- -
- -
Effective Tax Rate (%)
10.28
12.97
2.48
19.88
19.44
19
15.24
9.87
24.89
21.6
11.38
2.14
-23.34
-16.64
-14.63
Profit Margin (%)
-20
31
683
2,360
2,471
3,019
2,141
2,123
4,570
7,651
5,819
4,636
4,034
3,613
3,657
Working Capital
- -
- -
2
- -
- -
- -
- -
301
802
716
137
283
389
516
641
LT Debt
150
598
1,466
3,169
3,453
4,258
4,132
4,458
6,026
9,441
10,221
10,004
9,272
8,608
8,349
Total Equity
- -
42.26
3.95
10.93
9.84
11.26
9.97
6.65
37
18.02
8.57
1.17
- -
- -
- -
Return on Invested Capital (%)
- -
30.27
-0.2
10.87
9.49
9.6
8.64
6.21
34.96
17.21
8.17
1.49
- -
- -
- -
Return on Capital (%)
- -
52.96
3.55
12.24
10.31
10.6
9.43
6.57
40.68
19.19
8.28
0.93
-9.5
-7
-6.23
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
122
84
80
LT Borrowings
417
417
613
LT Finance Leases
64
32
27
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
418
418
418
Market Capitalization
16,670
14,666
19,184

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
5,813
5,687
5,655
Cash, Cash Equivalents & STI
3,365
3,163
3,162
Accounts Receivable, Net
1,710
1,821
1,748
Inventories
466
498
538
Total Current Liabilities
2,239
2,022
1,998
Payables & Accruals
- -
- -
- -
ST Debt
122
84
80
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
12.07%
9.67%
-7.16%
Free Cash Flow
28.87%
-46.88%
31.21%
Net Income, GAAP
-59.53%
-253.39%
-31.69%
Sales/Revenue/Turnover
21.48%
-13.76%
-4.18%
Total Cash Common Dividend
1,093.19%
35.04%
-65.68%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
821
1,050
954
1,041
3,867
2025
672
960
- -
1,032
3,705
2026
809
980
904
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.03
0.01
-0.35
-1.89
-2.19
2025
-0.13
0.14
- -
-1.43
-1.48
2026
-0.02
0.14
0.01
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
0.11
0.01
0.12
2025
0.01
0.01
- -
0.01
0.04
2026
0.01
0.01
0.01
- -
- -
Business
BGI Genomics Co., Ltd. (300676.SZ) provides genomic sequencing services and proteomic services to academic institutions, pharmaceutical companies, health care providers, and other organizations in China and internationally; offers DNA, RNA, customized sequencing solutions, and mass spectrometry services; delivers solutions for basic research in human, plant, animal, and microbial species, clinical research in human health, genetic testing and screening, drug discovery and development, agriculture, and biodiversity preservation; provides diagnostics and precision medicines for COVID-19, infectious diseases, and oncology, including COVID-19 PCR test kits and lab solutions; supplies reproductive health basic research and clinical application services, cancer and chronic disease prevention and translational medicine services, infection prevention and control services, multi-omics big data services, and comprehensive precision medical testing solutions. BGI Genomics operates as a subsidiary of BGI Group, founded in 1999 and headquartered in Shenzhen, China, with geographic operations spanning over 100 countries including Europe, North America, Asia-Pacific, and emerging markets in Asia and Africa. The company launched a new line of next-generation sequencing products in 2023, acquired a biotechnology firm specializing in AI-driven diagnostics in January 2023, formed strategic partnerships with pharmaceutical companies for drug discovery integration, and continues international expansion with new branches and multi-omics sequencing centers.